Drug Type Universal CAR-T |
Synonyms RJMty19 |
Target |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), T lymphocyte replacements |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-cell lymphoma recurrent | Phase 1 | CN | 30 Apr 2024 | |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Phase 1 | CN | 30 Oct 2023 | |
Idiopathic Inflammatory Myopathies | Phase 1 | CN | 30 Oct 2023 | |
Scleroderma, Systemic | Phase 1 | CN | 30 Oct 2023 | |
Systemic Lupus Erythematosus | Phase 1 | CN | 30 Oct 2023 | |
B-cell lymphoma refractory | Phase 1 | CN | 15 Jun 2022 | |
CD19-positive B-cell acute lymphoblastic leukemia | IND Approval | CN | 05 Mar 2024 |
NCT05453669 (NEWS) Manual | Phase 1 | 12 | (第4剂量组) | alrcdnrxys(ibawmfuvpk) = khqftfthnp xirdmeojly (rodnevznnc ) View more | Positive | 24 Aug 2023 |